Clinical Trials · NCT02668588

Extended-release of Octreotide (LF-PB) for the Treatment of Seroma

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Chemi S.p.A.
Enrollment
48
Start date
Oct 2015
Locations
7 sites, Italy
Primary endpoint
Incidence of seromas requiring an aspiration
View Octreotide compound reference